Creative Commons source reading · Multiple sclerosis and neuroimmunology
Demographic and clinical features of neuromyelitis optica: A review.
L Pandit; N Asgari; M Apiwattanakul; J Palace; F Paul; M I Leite; I Kleiter; T Chitnis; GJCF International Clinical Consortium & Biorepository for Neuromyelitis Optica
Originally published in Multiple sclerosis (Houndmills, Basingstoke, England) · 2015-04-28
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
The comparative clinical and demographic features of neuromyelitis optica (NMO) are not well known. In this review we analyzed peer-reviewed publications for incidence and prevalence, clinical phenotypes, and demographic features of NMO. Population-based studies from Europe, South East and Southern Asia, the Caribbean, and Cuba suggest that the incidence and prevalence of NMO ranges from 0.05-0.4 and 0.52-4.4 per 100,000, respectively. Mean age at onset (32.6-45.7) and median time to first relapse (8-12 months) was similar. Most studies reported an excess of disease in women and a relapsing course, particularly in anti-aquaporin 4 antibody (anti AQP4-IgG)-positive patients. Ethnicity may have a bearing on disease phenotype and clinical outcome. Despite limitations inherent to the review process, themes noted in clinical and demographic features of NMO among different populations promote a more global understanding of NMO and strategies to address it.
Conclusions
NMO epidemiology has largely been based on relatively small populations and data from tertiary hospitals. Many of these initial studies have yielded inconsistent findings. Confounding factors include the use of non-standardized diagnostic criteria, variability in assays for anti-AQP4 antibody, inconsistent inclusion of NMO-IgG seronegative patients, small study cohorts, and potential for selection bias. These factors limit the comparative assessment and statistical power of epidemiologic studies in NMO and NMOSD.
Editorial reading guide
- Which patient population and reference standard did the authors use?
- Was the finding validated in a separate cohort, and how might patient selection affect it?
